Harsh Parmar is an Oncology physician affiliated with Hackensack University Medical Center. OpenAlex indexes 83 publications with 226 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
92 2nd St
Hackensack, NJ 076012191
Telephone
551-996-8704Provider last certified this registry record 26 Jan 2022.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20258 payments
- Celgene CorporationProgram year20256 payments
- Alexion Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
59.2%Erythropoiesis-stimulating Agent57.7%Epoetin alfa100%Part B, office-administered≥26 patientsFactor Xa inhibitor1.5%Eliquis52%Xarelto48%Part D<11 patientsCancer & immunology
18.4%Thalidomide Analog16.5%Pomalyst57%Revlimid32%Lenalidomide11%Part D≥100 patientsProteasome Inhibitor0.9%Ninlaro100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
7.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.7%Valacyclovir100%Part D≥96 patientsShort-acting sulfonamides1.6%Sulfamethoxazole-Trimethoprim100%Part D≥24 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis
Leukemia & lymphoma/Leukemia and lymphoma
2025 - Complex Risk Assessment of Offset Wells Using Cognitive Analysis
International Petroleum Technology Conference
2025 - Impact of Extramedullary Disease on Survival Outcomes in Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel and Idecabtagene Vicleucel: A Comparative Analysis
Biology of Blood and Marrow Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Parrillo, MD
Hackensack University Medical Center
Andre Goy, MD
Hackensack University Medical Center
David Vesole, MD
Hackensack University Medical Center
Caron Rockman, MD
Hackensack University Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”